Incyte Corp. Stock Advances 3.4%, Outperforms Peers

Dow Jones12-16

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Incyte Corp. rallied 3.4% to $98.64 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.2% to 6,816.51 and Dow Jones Industrial Average falling 0.1% to 48,416.56.

Incyte Corp. closed 9.7% short of its 52-week high of $109.28, which the company achieved on November 12th.

The stock outperformed some of its peers, as Alnylam Pharmaceuticals Inc. fell 1.5% to $391.50, Bio-Techne Corp. rose 0.3% to $58.69, and BioMarin Pharmaceutical Inc. fell 2.23% to $52.12.

Trading volume totaled 2.8 million, compared to the 50-day average of 2.3 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

December 15, 2025 16:35 ET (21:35 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591624736?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 05:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591624736","market":"sh","top_or_hot":-1,"title":"Incyte Corp. Stock Advances 3.4%, Outperforms Peers","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  This article was automatically generated by Dow Jones using technology from Automated Insights. \n</p>\n<p>\n     Shares of Incyte Corp. rallied 3.4% to $98.64 on what proved to be an all-around poor trading session for the stock market, with the S&amp;P 500 Index falling 0.2% to 6,816.51 and Dow Jones Industrial Average falling 0.1% to 48,416.56. \n</p>\n<p>\n     Incyte Corp. closed 9.7% short of its 52-week high of $109.28, which the company achieved on November 12th. \n</p>\n<p>\n     The stock outperformed some of its peers, as Alnylam Pharmaceuticals Inc. fell 1.5% to $391.50, Bio-Techne Corp. rose 0.3% to $58.69, and BioMarin Pharmaceutical Inc. fell 2.23% to $52.12. \n</p>\n<p>\n     Trading volume totaled 2.8 million, compared to the 50-day average of 2.3 million. \n</p>\n<p>\n  Data source: Dow Jones Market Data, FactSet \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 16:35 ET (21:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Corp. Stock Advances 3.4%, Outperforms Peers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Corp. Stock Advances 3.4%, Outperforms Peers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-16 05:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  This article was automatically generated by Dow Jones using technology from Automated Insights. \n</p>\n<p>\n     Shares of Incyte Corp. rallied 3.4% to $98.64 on what proved to be an all-around poor trading session for the stock market, with the S&amp;P 500 Index falling 0.2% to 6,816.51 and Dow Jones Industrial Average falling 0.1% to 48,416.56. \n</p>\n<p>\n     Incyte Corp. closed 9.7% short of its 52-week high of $109.28, which the company achieved on November 12th. \n</p>\n<p>\n     The stock outperformed some of its peers, as Alnylam Pharmaceuticals Inc. fell 1.5% to $391.50, Bio-Techne Corp. rose 0.3% to $58.69, and BioMarin Pharmaceutical Inc. fell 2.23% to $52.12. \n</p>\n<p>\n     Trading volume totaled 2.8 million, compared to the 50-day average of 2.3 million. \n</p>\n<p>\n  Data source: Dow Jones Market Data, FactSet \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 16:35 ET (21:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591624736","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591624736","pubTimestamp":1765834500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Incyte Corp. rallied 3.4% to $98.64 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.2% to 6,816.51 and Dow Jones Industrial Average falling 0.1% to 48,416.56.Incyte Corp. closed 9.7% short of its 52-week high of $109.28, which the company achieved on November 12th.The stock outperformed some of its peers, as Alnylam Pharmaceuticals Inc. fell 1.5% to $391.50, Bio-Techne Corp. rose 0.3% to $58.69, and BioMarin Pharmaceutical Inc. fell 2.23% to $52.12.Trading volume totaled 2.8 million, compared to the 50-day average of 2.3 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗"},"translate_title":"Incyte Corp.股价上涨3.4%，跑赢同行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1.5},"content_text":"This article was automatically generated by Dow Jones using technology from Automated Insights. \n\n\n     Shares of Incyte Corp. rallied 3.4% to $98.64 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.2% to 6,816.51 and Dow Jones Industrial Average falling 0.1% to 48,416.56. \n\n\n     Incyte Corp. closed 9.7% short of its 52-week high of $109.28, which the company achieved on November 12th. \n\n\n     The stock outperformed some of its peers, as Alnylam Pharmaceuticals Inc. fell 1.5% to $391.50, Bio-Techne Corp. rose 0.3% to $58.69, and BioMarin Pharmaceutical Inc. fell 2.23% to $52.12. \n\n\n     Trading volume totaled 2.8 million, compared to the 50-day average of 2.3 million. \n\n\n  Data source: Dow Jones Market Data, FactSet \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 16:35 ET (21:35 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591624736","isCrawlerRequest":true}